Perigon Wealth Management LLC Buys 1,299 Shares of BioNTech SE (NASDAQ:BNTX)

Perigon Wealth Management LLC increased its stake in shares of BioNTech SE (NASDAQ:BNTX) by 40.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,505 shares of the company’s stock after acquiring an additional 1,299 shares during the period. Perigon Wealth Management LLC’s holdings in BioNTech were worth $476,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of BNTX. Baillie Gifford & Co. grew its stake in shares of BioNTech by 15.5% during the 3rd quarter. Baillie Gifford & Co. now owns 8,602,839 shares of the company’s stock worth $934,612,000 after acquiring an additional 1,152,541 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in shares of BioNTech by 4,861.2% during the 1st quarter. Envestnet Asset Management Inc. now owns 972,535 shares of the company’s stock worth $1,531,000 after purchasing an additional 952,932 shares during the last quarter. BlackRock Inc. raised its holdings in shares of BioNTech by 25.9% in the 1st quarter. BlackRock Inc. now owns 1,610,975 shares of the company’s stock valued at $274,768,000 after purchasing an additional 331,101 shares during the period. Renaissance Technologies LLC bought a new position in BioNTech during the first quarter worth about $42,711,000. Finally, Point72 Asset Management L.P. boosted its stake in shares of BioNTech by 175.1% during the 4th quarter. Point72 Asset Management L.P. now owns 302,600 shares of the company’s stock worth $45,457,000 after acquiring an additional 192,600 shares during the period. 15.52% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. JPMorgan Chase & Co. decreased their price objective on shares of BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a report on Friday, March 22nd. The Goldman Sachs Group dropped their target price on BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a report on Wednesday, February 28th. HC Wainwright cut their price objective on shares of BioNTech from $133.00 to $107.00 and set a “buy” rating for the company in a report on Tuesday, January 23rd. Canaccord Genuity Group reiterated a “buy” rating and issued a $171.00 price target on shares of BioNTech in a research note on Thursday, March 21st. Finally, UBS Group lowered their price objective on BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 27th. One analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, BioNTech currently has a consensus rating of “Hold” and an average price target of $120.40.

BioNTech Stock Up 1.6 %

Shares of NASDAQ:BNTX opened at $87.89 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.26 and a current ratio of 9.43. BioNTech SE has a 52-week low of $85.21 and a 52-week high of $129.10. The company has a market capitalization of $20.89 billion, a PE ratio of 21.33 and a beta of 0.23. The company has a fifty day moving average of $91.86 and a 200-day moving average of $97.80.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing the consensus estimate of $2.64 by ($0.59). The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $2.04 billion. BioNTech had a return on equity of 4.60% and a net margin of 24.26%. On average, equities analysts predict that BioNTech SE will post -1.67 EPS for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.